Search research articles
Contact Us
Filters
Showing results (81-90 of 113) with videos related to
Page
of 12
Sort By:
Blood Advances
|
April 17, 2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA
Sarah C Rutherford, Michael Herold, Wolfgang Hiddemann, et al.
Cancer
|
December 20, 2005
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma
Alan D Dosik, Morton Coleman, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
John P Leonard, Morton Coleman, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2014
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma
Martin Hutchings, Lale Kostakoglu, Jan Maciej Zaucha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2024
Automated Lugano Metabolic Response Assessment in <sup>18</sup>F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on <sup>18</sup>F-Fluorodeoxyglucose-Positron Emission Tomography
Skander Jemaa, Souhila Ounadjela, Xiaoyong Wang, et al.
Ejhaem
|
November 29, 2023
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials
Lale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Leukemia & Lymphoma
|
July 11, 2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design
Kristine Broglio, Lale Kostakoglu, Carol Ward, et al.
Blood Neoplasia
|
July 30, 2025
Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408
Frederique St-Pierre, Stephen M Broski, Zequn Sun, et al.
Plos One
|
June 15, 2018
ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy
Eva-Maria Ratai, Zheng Zhang, James Fink, et al.
Journal of the National Cancer Institute
|
December 18, 2016
General Biomarker Recommendations for Lymphoma
Lisa Rimsza, Yuri Fedoriw, Louis M Staudt, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 113) with videos related to
Sort By:
Page
of 12
Blood Advances
|
April 17, 2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA
Sarah C Rutherford, Michael Herold, Wolfgang Hiddemann, et al.
Cancer
|
December 20, 2005
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma
Alan D Dosik, Morton Coleman, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
John P Leonard, Morton Coleman, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2014
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma
Martin Hutchings, Lale Kostakoglu, Jan Maciej Zaucha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2024
Automated Lugano Metabolic Response Assessment in <sup>18</sup>F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on <sup>18</sup>F-Fluorodeoxyglucose-Positron Emission Tomography
Skander Jemaa, Souhila Ounadjela, Xiaoyong Wang, et al.
Ejhaem
|
November 29, 2023
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials
Lale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Leukemia & Lymphoma
|
July 11, 2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design
Kristine Broglio, Lale Kostakoglu, Carol Ward, et al.
Blood Neoplasia
|
July 30, 2025
Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408
Frederique St-Pierre, Stephen M Broski, Zequn Sun, et al.
Plos One
|
June 15, 2018
ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy
Eva-Maria Ratai, Zheng Zhang, James Fink, et al.
Journal of the National Cancer Institute
|
December 18, 2016
General Biomarker Recommendations for Lymphoma
Lisa Rimsza, Yuri Fedoriw, Louis M Staudt, et al.
Page
of 12